A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Inclusion criteria

• Are Japanese participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who agree to contraception requirements or participants who are individuals not of childbearing potential (INOCBP).
• Have a body mass index greater than or equal to (≥)25 kilograms per square meter (kg/m²)
• Have had a stable weight for the 3 months prior to screening. Stable weight is defined as less than 5 percent (%) body weight change.

Exclusion criteria

• Have known allergies to related compounds of macupatide or eloralintide, or any components of the formulations.
• Have a history of significant atopy, including severe allergic manifestations, or clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions.
• Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders, within the last 3 years, that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.
• Have been diagnosed with Type 1 or Type 2 diabetes mellitus.
• Have a history of chronic medical conditions involving the heart, liver, or kidneys.
• Have a history of any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
• Have a history or presence of a gastrointestinal (GI) disorder or previous surgery that impacts gastric emptying.
• Have had or plan to have during the study, a device-based or surgical treatment use for obesity.
• Have been treated, or plan to be treated, with prescription medications or other non approved drugs intended to promote weight loss, within 3 months prior to screening.
• Are currently enrolled or have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.
• Have previously completed or withdrawn from this study or have previously received macupatide or eloralintide.
• Have evidence of acute or chronic liver disease or pancreatic disease.